Ekaphop Sirachainan

Ekaphop Sirachainan

Auto-generated profile, based on publicly available information

Ekaphop Sirachainan

Mahidol University

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2024 in ESMO Open
Verified
Journal Article
Open access
KSKohei Shitara
Kohei Shitara
TFTania Fleitas
Tania Fleitas
HKH. Kawakami
H. Kawakami
GCGiuseppe Curigliano
Giuseppe Curigliano
YNYukiya Narita
Yukiya Narita
ESE. Smyth
E. Smyth
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer (GC), published in late 2022 and the updated ESMO Gastric Cancer Living Guideline published in July 2023, were adapted in August 2023, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with GC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with GC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), coordinated by ESMO and the Japanese Society of Medical Oncology (JSMO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different Asian regions represented by the 10 oncological societies. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with GC across the different regions of Asia, drawing on the evidence provided by both Western and Asian trials, whilst respecting the differences in screening practices, molecular profiling and age and stage at presentation. Attention is drawn to the disparity in the drug approvals and reimbursement strategies, between the different regions of Asia.

1 February 2006 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
CSChatchawan Silpakit
Chatchawan Silpakit
SSSuwanee Sirilerttrakul
Suwanee Sirilerttrakul
MJManmana Jirajarus
Manmana Jirajarus
TSThitiya Sirisinha
Thitiya Sirisinha
ESEkaphop Sirachainan
Ekaphop Sirachainan
VRVorachai Ratanatharathorn
Vorachai Ratanatharathorn

30 September 2012 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
CSCHONLAPHAT Sukasem
CHONLAPHAT Sukasem
ESEkaphop Sirachainan
Ekaphop Sirachainan
MCMontri Chamnanphon
Montri Chamnanphon
KPKhunthong Pechatanan
Khunthong Pechatanan
TSThitiya Sirisinha
Thitiya Sirisinha
WCWasun Chantratita
Wasun Chantratita
This study was designed to investigate the frequency of CYP2D6 polymorphisms and evaluate the association between genetic polymorphisms of CYP2D6 and tamoxifen therapeutic outcome in Thai breast cancer patients. We recruited 48 breast cancer patients who received adjuvant tamoxifen for evaluating CYP2D6 genetic polymorphisms using microarray-based technology. Associations between genotypes-phenotypes and disease free survival were analyzed. Median follow up time was 5.6 years. The mean age of the subjects was 50 years. The 3 common allelic frequencies were 43.8% (*10), 36.5 (*1) and 10.4% (*2) which are related to extensive metabolizer (EM) and intermediate metabolizer (IM) with 70.8% and 29.2 %, respectively. No association between CYP2D6 genotypes and DFS was demonstrated. Nevertheless, exploratory analysis showed statistically significant shorter DFS in the IM group of post-menopause patients (HR, 6.85; 95% CI, 1.48 -31.69; P = 0.005). Furthermore, we observed statistically significant shorter DFS of homozygous CYP2D6*10 when compared with heterozygous CYP2D6*10 and other genotypes (P=0.005). CYP2D6*10 was the most common genotype in our subjects. Post-menopause patients with homozygous CYP2D6*10 and IM have shorter DFS. To confirm this relationship, larger samples and comprehensively designed trials in Thailand are required.

1 June 2008 in Human Pathology
Verified
Journal Article
Closed access
NLNoppadol Larbcharoensub
Noppadol Larbcharoensub
JLJuvady Leopairat
Juvady Leopairat
ESEkaphop Sirachainan
Ekaphop Sirachainan
LNLadawan Narkwong
Ladawan Narkwong
TBThongchai Bhongmakapat
Thongchai Bhongmakapat
Tavan JanvilisriTavan Janvilisri
Tavan Janvilisri

1 August 2013 in Pharmacogenomics and Personalized Medicine
Verified
Journal Article
Open access
PDF file
ISInsee Sensorn
Insee Sensorn
ESEkaphop Sirachainan
Ekaphop Sirachainan
MCMontri Chamnanphol
Montri Chamnanphol
PSPorntip Supavilai
Porntip Supavilai
DPDarawan Pinthong
Darawan Pinthong
NTNarumol Trachu
Narumol Trachu
Background: Pharmacogenetic study of cytochrome P450 (CYP) gene CYP2D6 and tamoxifen outcomes remain controversial. Apart from CYP2D6, other drug-metabolizing enzymes and transporters also play a role in tamoxifen metabolic pathways. The aim of this study is to investigate the impact of CYP3A4/5, ABCB1, and ABCC2 polymorphisms on the risk of recurrence in Thai patients who received tamoxifen adjuvant therapy. Methods: Patients with early-stage breast cancer who received tamoxifen adjuvant therapy were recruited in this study. All six single-nucleotide polymorphisms (SNPs), including CYP3A4*1B (-392 A>G)/*18(878 T>C), CYP3A5*3(6986 G>A), ABCB1 3435 C>T, ABCC2*1C (-24 C>T), and ABCC2 68231 A>G, were genotyped using real-time polymerase chain reaction assays. The impacts of genetic variants on disease-free survival (DFS) were analyzed using the Kaplan–Meier method and Cox regression analysis. Results: The ABCB1 3435 C>T was found to have the highest allele frequency among other variants; however, CYP3A4*1B/*18 could not be found in this study. Patients with heterozygous ABCB1 3435 CT genotype showed significantly shorter DFS than those with homozygous 3435 CC genotype (P = 0.041). In contrast, patients who carried homozygous 3435 TT genotype showed no difference in DFS from wild-type 3435 CC patients. Cox regression analysis showed that the relative risk of recurrence was increased by five times (P = 0.043; hazard ratio = 5.11; 95% confidence interval: 1.05–24.74) in those patients carrying ABCB1 3435 CT genotype compared to those with ABCB1 3435 CC. Conclusion: ABCB1 3435 C>T is likely to have a clinically significant impact on recurrence risk in Thai patients with breast cancer who receive tamoxifen adjuvant therapy.

1 October 2012 in Pharmacogenomics and Personalized Medicine
Verified
Journal Article
Open access
PDF file
CSCHONLAPHAT Sukasem
CHONLAPHAT Sukasem
ESEkaphop Sirachainan
Ekaphop Sirachainan
SJSureerat Jaruhathai
Sureerat Jaruhathai
NTNarumol Trachu
Narumol Trachu
RPRavat Panvichian
Ravat Panvichian
MCMontri Chamnanphon
Montri Chamnanphon
Aim: We evaluated single nucleotide polymorphisms (SNPs) of CYP2D6 to identify those that influence the efficiency of tamoxifen in adjuvant treatment of breast cancer through a matched case–control study. Methods: Peripheral blood DNA was collected from 20 patients with disease recurrence during adjuvant tamoxifen treatment and from 19 patients who had completed 5 years of tamoxifen therapy without recurrence of breast cancer. CYP2D6*4 (1846G > A; rs3892097), CYP2D6*10 (100C > T, rs1065852), and CYP2D6*5 (deletion) were genotyped. The correlation between disease-free survival (DFS) and genotype and clinical outcome were assessed using Kaplan–Meier analysis and a log-rank test. Results: We found the allelic frequency of CYP2D6*10 during this study. Patients with the CYP2D6*10 homozygous variant T/T genotype had a significantly shorter median of DFS than those with C/T (P = 0.036), but DFS was not significantly different from that of patients with the C/C genotype (P = 0.316). One patient who was a carrier both of CYP2D6 G/A (1846G > A) and T/T (100C > T) had DFS of 22.7 months. Conclusions: This study demonstrated that CYP2D6*10/*10 was significantly associated with shorter DFS in Thai breast cancer patients receiving tamoxifen. This was a pilot study investigating the correlation of CYP2D6 polymorphisms and their influence on clinical outcomes in Thai estrogen receptor-positive breast cancer patients.